PT  - JOURNAL ARTICLE
ED  - ,
TI  - Imiquimod for superficial and in situ skin malignancy
AID  - 10.1136/dtb.2009.09.0040
DP  - 2009 Oct 01
TA  - Drug and Therapeutics Bulletin
PG  - 113--116
VI  - 47
IP  - 10
4099  - http://dtb.bmj.com/content/47/10/113.short
4100  - http://dtb.bmj.com/content/47/10/113.full
SO  - Drug Ther Bull2009 Oct 01; 47
AB  - Relevant BNF section: 13.7 Imiquimod, an immune response modifier, is marketed as Aldara 5% cream (Meda) and licensed for treating adults with small superficial basal cell carcinomas (BCCs).1 Numerous uses outside the licensed indications (i.e. ‘off-label’) have been proposed and practised, including as treatment for pre-cancerous conditions such as Bowen's disease (squamous cell carcinoma in situ) and lentigo maligna (an in situ precursor of melanoma).2,3 Here we review the use of imiquimod for small superficial primary BCC in adults, Bowen's disease and lentigo maligna.